ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Establishment and application of multiple cross displacement amplification coupled with lateral flow biosensor (MCDA-LFB) for visual and rapid detection of Candida glabrata.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid and ultrasensitive detection ofFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background(Candida glabrata C. glabrata) is classified as a high-priority pathogen by the World Health Organization (WHO). It causes mucosal and deep infections in immunocompromised individuals, yet its diagnosis currently relies on slow culture processes. This highlights the urgent need for rapid and accurate detection methods.
methodsTen primers targeting different regions of the C. glabrata ITS2 gene were designed to create a multiple cross displacement amplification (MCDA) assay coupled with a nanoparticle lateral flow biosensor (LFB). Following optimisation of temperature and time, the multiple cross displacement amplification coupled with lateral flow biosensor (MCDA-LFB) system was employed to detect C. glabrata DNA in clinical specimens.
resultsUnder optimal conditions (63 °C, 40 min), the C. glabrata-MCDA-LFB assay achieved a limit of detection (LoD) of 10 fg/µL.The assay successfully detected all C. glabrata strains tested and demonstrated no cross-reactivity with non-C. glabrata isolates. Findings showed that the C. glabrata-MCDA-LFB assay promptly and successfully detected all 57 C. glabrata-positive samples among 240 clinical specimens identified by traditional culture methods. The entire process, including sample processing (20 min), the MCDA reaction (40 min) and result documentation (2 min), was completed within 62 min.
conclusionThe C. glabrata-MCDA-LFB assay developed in this study is a rapid, simplified, sensitive and specific technique that is straightforward to use. It can be used to screen for or diagnose C. glabrata infections in clinical settings, particularly in regions with limited resources.
Indexed as
Identifiers
41428300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.